Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05365659 · ClinicalTrials.gov registry record · Phase 1
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
A Phase 1 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma, sponsored by Iksuda Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 13
- Study locations
NCT05365659 is a Phase 1 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma that is actively recruiting participants, run by Iksuda Therapeutics. The registered enrollment target is 140 participants, below the 217-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (35% lower). The trial reports 13 study locations across 7 states.
The verdict
NCT05365659, a Phase 1 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma, is actively recruiting participants, sponsored by Iksuda Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 13
- Study locations
Study Summary
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).
Conditions Studied
Interventions
- DRUG IKS03
Study Locations (13)
Other
- La Fondazione e l'Istituto di Candiolo - Candiolo
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele - Milan
- Istituto Europeo Clinico Humanitas - Milan
- Istituto Europeo di Oncologia - Milan
- Institut Catala D'Oncologia - Badalona
- Hospital Universitario Quironsalud Madrid - Madrid
- Hospital Clinico Universitario de Salamanca - Salamanca
Maryland
- University of Maryland Baltimore - Baltimore
New South Wales
- Westmead Hospital - Westmead
South Australia
- Royal Adelaide Hospital - Adelaide
Tasmania
- Royal Hobart Hospital - Hobart
Western Australia
- Linear Clinical Research - Perth
Quebec
- Jewish General Hospital - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2023-09-05 |
| Est. Completion | 2028-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05365659
The ClinicalTrials.gov registry entry for NCT05365659 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 217-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (35% lower). The listed sponsor is Iksuda Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which IKS03 is the first listed.
NCT05365659 reports 13 study locations spanning 7 distinct geographic areas - top geographies include Other, Maryland, New South Wales.
Frequently Asked Questions
What is clinical trial NCT05365659 about?
NCT05365659 is a clinical study titled "IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas". This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphom...
What is the current status of trial NCT05365659?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2023-09-05. Estimated completion is 2028-09.
What conditions does trial NCT05365659 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, B-cell Lymphoma, B-Cell Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05365659?
The interventions under investigation include: IKS03 (DRUG).
Who is sponsoring clinical trial NCT05365659?
This trial is sponsored by Iksuda Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05365659 being conducted?
This trial has 13 study locations across Maryland, New South Wales, South Australia, Tasmania, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
RECRUITING · Phase 1
-
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.